{
    "id": 19921,
    "fullName": "IL6 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "IL6 positive indicates the presence of the IL6 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3569,
        "geneSymbol": "IL6",
        "terms": [
            "IL6",
            "BSF-2",
            "BSF2",
            "CDF",
            "HGF",
            "HSF",
            "IFN-beta-2",
            "IFNB2",
            "IL-6"
        ]
    },
    "variant": "positive",
    "createDate": "03/21/2016",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4308,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gemzar (gemcitabine) and Platinol (cisplatin) inhibited tumor growth in non-small cell lung cancer cells harboring EGFR E746-A750del and with intact autocrine IL6 signaling in xenongraft models (PMID: 26744529).",
            "molecularProfile": {
                "id": 17709,
                "profileName": "EGFR E746_A750del IL6 pos IL6R pos"
            },
            "therapy": {
                "id": 1467,
                "therapyName": "Cisplatin + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4299,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 in combination with Taxol (paclitaxel) inhibited tumor growth and STAT signaling in non-small cell lung cancer cells harboring EGFR del E746-A750 and with intact autocrine IL6 signaling in xenograft models (PMID: 26744529).",
            "molecularProfile": {
                "id": 17709,
                "profileName": "EGFR E746_A750del IL6 pos IL6R pos"
            },
            "therapy": {
                "id": 3482,
                "therapyName": "MEDI5117 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4312,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 in combination with Alimta (pemetrexed) inhibited tumor growth in xenograft models of non-small cell lung cancer cells harboring EGFR del E746-A750 and with intact autocrine IL6 signaling (PMID: 26744529).",
            "molecularProfile": {
                "id": 17709,
                "profileName": "EGFR E746_A750del IL6 pos IL6R pos"
            },
            "therapy": {
                "id": 3489,
                "therapyName": "MEDI5117 + Pemetrexed",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4300,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 in combination with Iressa (gefitinib) inhibited tumor growth more than either compound alone in xenograft models of non-small cell lung cancer cells harboring EGFR E746-A750del and with intact autocrine IL6 signaling (PMID: 26744529).",
            "molecularProfile": {
                "id": 17709,
                "profileName": "EGFR E746_A750del IL6 pos IL6R pos"
            },
            "therapy": {
                "id": 3483,
                "therapyName": "Gefitinib + MEDI5117",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4298,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 inhibited tumor growth in xenograft models of non-small cell lung cancer cells harboring EGFR E746-A750del and with intact autocrine IL6 signaling (PMID: 26744529).",
            "molecularProfile": {
                "id": 17709,
                "profileName": "EGFR E746_A750del IL6 pos IL6R pos"
            },
            "therapy": {
                "id": 3481,
                "therapyName": "MEDI5117",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4307,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 in combination with Gemzar (gemcitabine) and Platinol (cisplatin) inhibited tumor growth more than MEDI5117 or gemcitabine with cisplatin in non-small cell lung cancer cells harboring EGFR E746-A750del with intact autocrine IL6 signaling in xenograft models (PMID: 26744529).",
            "molecularProfile": {
                "id": 17709,
                "profileName": "EGFR E746_A750del IL6 pos IL6R pos"
            },
            "therapy": {
                "id": 3486,
                "therapyName": "Cisplatin + Gemcitabine + MEDI5117",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4305,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 inhibited growth of multiple solid tumor cell lines with expression of IL6R and IL6 and evidence of autocrine IL6 signaling in culture and xenografts (PMID: 26744529).",
            "molecularProfile": {
                "id": 20356,
                "profileName": "IL6 pos IL6R pos"
            },
            "therapy": {
                "id": 3481,
                "therapyName": "MEDI5117",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4310,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 in combination with Hycamtin (toptecan) inhibited tumor growth in ovarian cancer xenograft models with IL6 autocrine signaling (PMID: 26744529).",
            "molecularProfile": {
                "id": 20356,
                "profileName": "IL6 pos IL6R pos"
            },
            "therapy": {
                "id": 3488,
                "therapyName": "MEDI5117 + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4309,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 in combination with Adriamycin (doxorubicin) inhibited tumor growth in xenograft models of ovarian cancer cells with expression of IL6 and IL6R and evidence of autocrine IL6 signaling (PMID: 26744529).",
            "molecularProfile": {
                "id": 20356,
                "profileName": "IL6 pos IL6R pos"
            },
            "therapy": {
                "id": 3487,
                "therapyName": "Doxorubicin + MEDI5117",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4297,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 inhibited tumor growth in ovarian cancer xenograft models that secrete IL6 and have cell surface expression of IL6R, and have evidence of autocrine IL6 signaling (PMID: 26744529).",
            "molecularProfile": {
                "id": 20356,
                "profileName": "IL6 pos IL6R pos"
            },
            "therapy": {
                "id": 3481,
                "therapyName": "MEDI5117",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4314,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human breast cancer cell line with amplification of Erbb2, loss of Pten and autocrine IL6 signaling was resistant to Herceptin (trastuzumab) in culture and in xenograft models (PMID: 26744529).",
            "molecularProfile": {
                "id": 20362,
                "profileName": "ERBB2 amp IL6 pos IL6R pos PTEN loss"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4313,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 inhibited growth of Herceptin (trastuzumab) resistant breast cancer cells with amplification of Erbb2, loss of Pten and autocrine IL6 signaling in culture and in xenograft models (PMID: 26744529).",
            "molecularProfile": {
                "id": 20362,
                "profileName": "ERBB2 amp IL6 pos IL6R pos PTEN loss"
            },
            "therapy": {
                "id": 3481,
                "therapyName": "MEDI5117",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17709,
            "profileName": "EGFR E746_A750del IL6 pos IL6R pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20355,
            "profileName": "IL6 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20356,
            "profileName": "IL6 pos IL6R pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20362,
            "profileName": "ERBB2 amp IL6 pos IL6R pos PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}